Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-classhealthcare technologies, is proud to announce that its portfolio company arGEN-X N.V. (arGEN-X or the company), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has successfully completed its Initial Public Offering, which was launched on 23 June 2014 (“IPO” or the “Offering”). arGEN-X shares will be listed on Euronext Brussels and begin trading on an “if-and-when-issued-or-delivered” basis on Thursday 10 July 2014 under the symbol “ARGX”.